Abbott Laboratories (ABT) Price Target Cut to $112 by Evercore ISI
Evercore ISI analyst reduced Abbott Laboratories (ABT) price target to $112 from $120, while keeping an Outperform rating. The cut comes amid a review of growth expectations in the healthcare sector.
Key Numbers
Evercore ISI analyst reduced Abbott Laboratories (ABT) price target to $112 from $120, while keeping an Outperform rating. The cut comes amid a review of growth expectations in the healthcare sector.
Details of the Change
| Item | Previous Value | New Value |
|---|---|---|
| Price Target | $120 | $112 |
| Rating | Outperform | Outperform (unchanged) |
Analyst's Rationale
The analyst noted that the price target reduction reflects an update to the company's financial model, taking into account recent market pressures on the medical device sector. However, the analyst remains optimistic about the company's long-term performance, citing its diversified product portfolio and strong brand.
Context
This adjustment follows a period of volatile performance for ABT stock. Meanwhile, many other analysts still view the company as an attractive investment opportunity in the innovative healthcare space. According to recent data, ABT was listed among the top 10 innovative healthcare stocks.
Conclusion
While the price target cut reflects some near-term caution, the maintained Outperform rating signals confidence in the company's ability to overcome challenges. Investors are advised to monitor upcoming financial reports to assess actual performance.
Frequently Asked Questions
Found this useful? Share it